Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Raymond James

What To Know About Raymond James's Upgrade of Arthur J. Gallagher

Raymond James upgraded its rating of Arthur J. Gallagher (NYSE:AJG) to Strong Buy with a price target of $195.00, changing its price target from $185.00 to $195.00. Shares of Arthur J. Gallagher are trading down 1.07% over the last 24 hours, at $166.68 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Upgrades

Benzinga

Why These Analysts Cut Price Target On Teleflex

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why These Analysts Are Bullish On Gilead's Q1 Earnings

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,…

Benzinga

Apple Analysts See Production Issues As Transitory, Recommend Buying On Weakness Following Q2 Results

Apple Inc (NASDAQ: AAPL) reported better-than-expected second-quarter earnings and revenues.

Benzinga

'Long Road Of Rebuilding Begins': PayPal Analysts React To Mixed Q1 Earnings Report

Shares of PayPal Holdings Inc (NASDAQ: PYPL) gained 11% on Thursday after the company reported a revenue beat but cut its 2022 guidance.

Benzinga

Improved Costs, Reels Growth, Attractive Multiples: What 6 Analysts Are Saying About Meta Platforms Post Earnings

Shares of social media and metaverse company Meta Platforms Inc (NASDAQ: FB) traded higher Wednesday after market close. The move came after the company reported first-quarter financial results. Here are the key takeaways from the earnings report from analysts.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current…

Benzinga

Occidental Petroleum Whale Trades For April 28

Someone with a lot of money to spend has taken a bearish stance on Occidental Petroleum (NYSE:OXY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Chipotle Can Navigate Food Cost Concerns, Menu Price Increases: 4 Analysts React To Earnings Report

Rising food costs, menu price increases and store growth were the big topics highlighted by analysts who cover restaurant company Chipotle Mexican Grill, Inc. (NYSE: CMG). Here are the key analyst takeaways.

Benzinga

Raymond James Maintains Strong Buy Rating for Mohawk Industries: Here's What You Need To Know

Raymond James has decided to maintain its Strong Buy rating of Mohawk Industries (NYSE:MHK) and lower its price target from $220.00 to $190.00. Shares of Mohawk Industries are trading up 0.59% over the last 24 hours, at $125.44 per share.

Benzinga

Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

Benzinga

Analysts Share Their View On Activision Blizzard Post Q1 Performance

Analysts offered their views on Activision Blizzard, Inc (NASDAQ:ATVI) post Q1 FY22 results. Raymond James saw ATVI's Q1 results significantly below expectations, driven by continued weakness in Call of Duty and a low ebb of content in Blizzard. It continued to see sizable headwinds for Call of Duty through the rest of the year until the anticipated release…

Benzinga

Check Out What Whales Are Doing With JNJ

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Raymond James Lists Marvell's Sources Of Growth, Profitability Leading To Upgrade

Two analysts re-rated Marvell Technology Inc (NASDAQ: MRVL) today.

Benzinga

Here's Why Raymond James Sees 75.4% Upside In AMD; Upgrades To Strong Buy

Raymond James analyst Chris Caso upgraded Advanced Micro Devices Inc (NASDAQ:AMD) to Strong Buy from Outperform with a $160 price target. The price target implies a 75.4% upside. As Caso became more concerned about cycle risks, given the potential for slowing consumer demand and elevated inventory levels at customers, he favored those semi companies with…

Benzinga

Why AMD Shares Are Trading Higher Today

Advanced Micro Devices, Inc. (NASDAQ: AMD) shares are trading higher Monday following positive analyst coverage from Raymond James. Raymond James analyst Chris Caso upgraded the stock from Outperform to Strong Buy and announced a $160 price target.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Analysts Think Intuitive Surgical Painted 'Cautious Picture' For Procedure Guidance

Wells Fargo writes that despite the beat in Q1, Intuitive Surgical Inc (NASDAQ:ISRG) sounded cautious on U.S. capital placements, given rising interest rates and inflationary pressure at hospitals. "We think this commentary was partly driven by the need to recalibrate Street models for fewer trade-ins as the number of legacy Si systems declines. Overall,…

Benzinga

These Netflix Analysts Aren't Confident Of A Turnaround Within The Next 18 Months

Netflix Inc (NASDAQ: NFLX) reported a revenue miss and a loss of net paid adds for the first quarter.

Benzinga

Analysts Bump Up CSX Price Target Post Q1 Results

CSX Corp's (NASDAQ:CSX) price target has been raised by two analysts post Q1 results. Raymond James analyst Patrick Tyler Brown raised CSX’s price target to $40 (an upside of 10%) from $39 while maintaining the Outperform rating on the shares. The analyst states that CSX continues to execute its PSR initiatives to drive operational improvement,…

Benzinga

What Does Raymond James, Wells Fargo Have To Say On Abbott's Q1 Earnings

Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8%

Benzinga

Johnson & Johnson Whale Trades For April 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 strange trades.

Benzinga

Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Benzinga

Raymond James Lists Key Takeaways From Qualtrics' Proxy Filing

Qualtrics International Inc's (NASDAQ:XM) April 15 proxy filing also disclosed new ACV and retention metrics pertinent to investors, Raymond James observed. Qualtrics added $365.1 million in new software ACV billings in 2021, effectively aligning with the target performance level of $365.0 million. Total research services billing of $160.1 million also were effectively in-line…

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations